Overview

Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases

Status:
Terminated
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen, consisting of fludarabine, cyclophosphamide and low dose total body irradiation (TBI), is designed for the treatment of patients with advanced and/or high risk diseases.
Phase:
N/A
Details
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Treatments:
Cyclophosphamide
Fludarabine
Fludarabine phosphate